Doering P L, Araujo O E, Frohnapple D J, LaMarre A S, Flowers F P
College of Pharmacy, University of Florida, Gainesville 32610.
Ann Pharmacother. 1992 Feb;26(2):155-61. doi: 10.1177/106002809202600201.
The primary objectives of this study were to determine how dermatologists currently prescribe isotretinoin and to determine if the potential for adverse effects, especially those affecting the fetus, has influenced dermatologists' prescribing patterns.
A survey was mailed to 1618 dermatologists practicing in the US. The survey comprised 22 multiple-choice and fill-in-the-blank questions about the use of isotretinoin. Eight weeks were allowed for completion and return of the survey.
The setting of the study included dermatologists in private practice, those with academic appointments, those in administration, and a few dermatologists in other pursuits.
The membership roster of the American Academy of Dermatology served as the sampling frame from which survey recipients were drawn. After arranging the list by zip code, a sample of dermatologists was taken by systematically choosing every fifth name on the list, giving the researchers the total sample of 1618 physicians.
Questions were organized into the following sections: (1) practice status of respondent, (2) prescriber demographics, (3) influence of adverse effects on prescribing, (4) prescribing practices, (5) discontinuation of therapy, and (6) restriction of isotretinoin to dermatologists. The survey concluded by providing participants the opportunity to make further observations or comments.
Of the 1618 surveys mailed, 670 usable responses were received (41.4 percent). Most respondents were in private practice. Data show that dermatologists were prescribing isotretinoin for indications other than those contained in the official labeling. Most physicians reported that they do perform a pregnancy test before prescribing the drug, and many require written informed consent before prescribing. Physicians report that, in general, their patients tolerate isotretinoin well. When therapy is discontinued, it is most often secondary to hypertriglyceridemia. Dermatologists believe that they should have sole authority for prescribing isotretinoin.
Our results show that there is still a need for emphasizing the limited indications for isotretinoin and a need for effective patient education for women of childbearing potential who may be prescribed this drug.
本研究的主要目的是确定皮肤科医生目前如何开具异维甲酸处方,并确定不良反应的可能性,尤其是那些影响胎儿的不良反应,是否影响了皮肤科医生的处方模式。
向在美国执业的1618名皮肤科医生邮寄了一份调查问卷。该调查包括22个关于异维甲酸使用的多项选择题和填空题。允许八周时间完成并返还调查问卷。
研究背景包括私人执业的皮肤科医生、有学术职务的医生、行政人员以及少数从事其他工作的皮肤科医生。
美国皮肤科协会的会员名册作为抽样框架,从中抽取调查对象。按邮政编码排列名单后,通过系统地选择名单上的每第五个名字抽取了一个皮肤科医生样本,研究人员共获得了1618名医生的样本。
问题分为以下几个部分:(1)应答者的执业状况,(2)开处方者的人口统计学特征,(3)不良反应对处方的影响,(4)处方习惯,(5)治疗中断情况,以及(6)异维甲酸仅限皮肤科医生使用。调查最后为参与者提供了进一步发表意见或评论的机会。
在邮寄的1618份调查问卷中,收到了670份有效回复(41.4%)。大多数应答者为私人执业医生。数据显示,皮肤科医生开具异维甲酸的适应症超出了官方标签所包含的范围。大多数医生报告说,他们在开处方前确实会进行妊娠试验,并且许多医生在开处方前需要书面知情同意书。医生报告说,总体而言,他们的患者对异维甲酸耐受性良好。当治疗中断时,最常见的原因是高甘油三酯血症。皮肤科医生认为他们应该拥有开具异维甲酸的唯一权力。
我们的结果表明,仍然需要强调异维甲酸的适应症有限,并且需要对可能被开具此药的有生育潜力的女性进行有效的患者教育。